TrialA Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
Trial details
- Registry ID
- NCT06981078
- Phase
- Phase 2
Drug research
Verekitug
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as UPB-101
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPDNCT06981078 | UPB | Phase 2 | Active not recruiting | 2027-10Estimated |
| A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)NCT06966479 | UPB | Phase 2 | Active not recruiting | 2027-09Estimated |
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
Trial details
- Registry ID
- NCT06966479
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |